Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat blood cancer: experimental drug enters human testing

NCT ID NCT05650632

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 4 times

Summary

This study tests an experimental drug called etentamig (ABBV-383) in about 210 adults whose multiple myeloma has come back or stopped responding to other treatments. The main goals are to find the best dose and check for side effects. Participants receive the drug as an infusion every 28 days for up to 3 years, with regular monitoring at the clinic.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have measurable disease as outlined in the protocol. * Eastern Cooperative Oncology Group (ECOG) performance of \<= 2. Arm C and Arm D: ECOG performance of \<= 1. * Relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) 2016 criteria. * Must be naïve to treatment with etentamig (ABBV-383). * Arm A: Must have received at least 3 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD), and an anti-CD38 monoclonal antibody. * Arm B: Must have received at least 2 or more lines of therapy, including exposure to a PI, an IMiD, an anti-CD38 monoclonal antibody, and a prior B-cell maturation antigen (BCMA)-targeted therapy (must be an anti-drug conjugate \[ADC\] or chimeric antigen receptor T-cell \[CAR-T\] directed against BCMA). * Arm C: Must have received at least 2 or more lines of therapy, including exposure to a PI, an IMiD, and an anti-CD38 monoclonal antibody. Must be suitable for outpatient administration of etentamig (ABBV-383). * Arm D: Must have received at least 1 and no more than 3 prior lines of therapy, including exposure to a PI, an IMiD, or an anti-CD38 monoclonal antibody. Must be suitable for outpatient administration of etentamig (ABBV-383). Exclusion Criteria: * Arm A: Received BCMA-targeted therapy. * Arm C and Arm D: Rapidly progressing disease per investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    41 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP - Hopital Saint-Antoine /ID# 252326

    COMPLETED

    Paris, 75012, France

  • Atrium Health Wake Forest Baptist Medical Center /ID# 251165

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • Baptist Memorial Hospital /ID# 280677

    NOT_YET_RECRUITING

    Memphis, Tennessee, 38120, United States

  • CHU Poitiers - La miletrie /ID# 251219

    RECRUITING

    Poitiers, Vienne, 86000, France

  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 251196

    RECRUITING

    Nantes, Pays de la Loire Region, 44000, France

  • Fort Wayne Medical Oncology And Hematology /ID# 268179

    RECRUITING

    Fort Wayne, Indiana, 46804, United States

  • Franciscan St. Francis Health /ID# 280928

    RECRUITING

    Indianapolis, Indiana, 46237, United States

  • Fred Hutchinson Cancer Center. /ID# 267940

    RECRUITING

    Seattle, Washington, 98109-4405, United States

  • HCL - Hopital Lyon Sud /ID# 251223

    RECRUITING

    Pierre-Bénite, Rhone, 69495, France

  • Hadassah Medical Center-Hebrew University /ID# 252079

    RECRUITING

    Jerusalem, Jerusalem, 91120, Israel

  • Highlands Oncology Group - Springdale /ID# 267742

    RECRUITING

    Springdale, Arkansas, 72762, United States

  • Hope And Healing Cancer Services /ID# 268536

    RECRUITING

    Hinsdale, Illinois, 60521, United States

  • Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 252101

    COMPLETED

    Créteil, Paris, 94010, France

  • Hospital Universitario Marques de Valdecilla /ID# 251528

    RECRUITING

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 251545

    COMPLETED

    Majadahonda, Madrid, 28222, Spain

  • Hospital Universitario de Salamanca /ID# 251529

    RECRUITING

    Salamanca, 37711, Spain

  • Institut Paoli-Calmettes /ID# 252100

    COMPLETED

    Marseille, Bouches-du-Rhone, 13009, France

  • Juravinski Cancer Centre /ID# 252053

    RECRUITING

    Hamilton, Ontario, L8V 1C3, Canada

  • Maryland Oncology Hematology - Silver Spring /ID# 268562

    NOT_YET_RECRUITING

    Silver Spring, Maryland, 20904, United States

  • Mayo Clinic - Rochester /ID# 251164

    RECRUITING

    Rochester, Minnesota, 55905-0001, United States

  • Mayo Clinic Arizona /ID# 251405

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Medical Oncology Hematology Consultants /ID# 268560

    RECRUITING

    Newark, Delaware, 19713, United States

  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167

    RECRUITING

    New York, New York, 10065-6007, United States

  • Mt Sinai /ID# 251166

    RECRUITING

    New York, New York, 10029-6542, United States

  • NHO Revive Research Institute, LLC /ID# 267869

    RECRUITING

    Lincoln, Nebraska, 68506, United States

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Northwest Medical Specialties Tacoma /ID# 267117

    RECRUITING

    Tacoma, Washington, 98405, United States

  • Odense University Hospital /ID# 251261

    RECRUITING

    Odense, Region Syddanmark, 5000, Denmark

  • Oncology Consultants /ID# 268323

    RECRUITING

    Houston, Texas, 77030, United States

  • Ottawa Hospital Research Institute /ID# 252151

    COMPLETED

    Ottawa, Ontario, K1H 8L6, Canada

  • Rabin Medical Center. /ID# 251330

    RECRUITING

    Petah Tikva, Central District, 4941492, Israel

  • Rocky Mountain Cancer Centers - Aurora /ID# 268574

    RECRUITING

    Aurora, Colorado, 80012, United States

  • Tel Aviv Sourasky Medical Center /ID# 251573

    RECRUITING

    Tel Aviv, Tel Aviv, 6423906, Israel

  • Texas Oncology - Central/South Texas /ID# 268563

    RECRUITING

    Austin, Texas, 78705, United States

  • Texas Oncology - Dallas - Worth Street /ID# 280064

    RECRUITING

    Dallas, Texas, 75246, United States

  • Texas Oncology - Northeast Texas /ID# 268877

    RECRUITING

    Tyler, Texas, 75702, United States

  • The Chaim Sheba Medical Center /ID# 251329

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The Christie Hospital /ID# 251774

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • Tulane University School of Medicine /ID# 251204

    RECRUITING

    New Orleans, Louisiana, 70112, United States

  • University College London Hospital /ID# 251357

    RECRUITING

    London, Greater London, NW1 2BU, United Kingdom

  • University Of Cincinnati Medical Center /ID# 251746

    RECRUITING

    Cincinnati, Ohio, 45219, United States

  • University of North Carolina /ID# 251203

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • Vanderbilt Ingram Cancer Center /ID# 252470

    RECRUITING

    Nashville, Tennessee, 37232-0021, United States

  • Vejle Sygehus /ID# 251260

    RECRUITING

    Vejle, Region Syddanmark, 7100, Denmark

  • Virginia Cancer Specialists - Fairfax /ID# 268559

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Willamette Valley Cancer Institute and Research Center /ID# 267088

    RECRUITING

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.